Elimination of extracellular dopamine in the medial prefrontal cortex of conscious mice analyzed using selective enzyme and uptake inhibitors

Journal of Physiology and Pharmacology

Volumn 67, Issue 2, 2016, Pages 301-309

  Tammimaki, Anne ^a   Aonurm Helm, A ^a,b   Kaenmaki, M ^a   Mannisto, P T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Catechol O methyltransferase; Dopamine; Dorsal striatum; Microdialysis; Monoamine oxidase; Prefrontal cortex; Sulfotransferases

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID; PARGYLINE; REBOXETINE; TOLCAPONE; 3,4 DIHYDROXYPHENYLACETIC ACID; ADRENERGIC RECEPTOR AFFECTING AGENT; BENZOPHENONE DERIVATIVE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MORPHOLINE DERIVATIVE; NITROPHENOL;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; DYNAMICS; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMOBILITY; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; SINGLE DRUG DOSE; ANIMAL; C57BL MOUSE; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; SYNAPTOSOME;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; DOPAMINE; FEMALE; HOMOVANILLIC ACID; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOAMINE OXIDASE INHIBITORS; MORPHOLINES; NITROPHENOLS; PARGYLINE; PREFRONTAL CORTEX; REBOXETINE; SYNAPTOSOMES; TOLCAPONE;

EID: 84971500294     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Heidbreder CA, Groenewegen HJ. The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehav Rev 2003; 27: 555-579.
2. Puig MV, Antzoulatos EG, Miller EK. Prefrontal dopamine in associative learning and memory. Neuroscience 2014; 282C: 217-229.
3. Cassaday HJ, Nelson AJ, Pezze MA. From attention to memory along the dorsal-ventral axis of the medial prefrontal cortex: some methodological considerations. Front Syst Neurosci 2014; 8: 160. doi: 10.3389/fnsys.2014.00160.
4. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004; 28: 771-784.
5. Cass WA, Zahniser NR, Flach KA, Gerhardt GA. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J Neurochem 1993; 61: 2269-2278.
6. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56: 331-349.
7. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
8. Dahlin A, Xia L, Kong W, Hevner R, Wang J. Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 2007; 146: 1193-1211.
9. Trendelenburg U. The interaction of transport mechanisms and intracellular enzymes in metabolizing systems. J Neural Transm Suppl 1990; 32: 3-18.
10. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593-628.
11. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95: 9991-9996.
12. Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002; 15: 246-256.
13. Yavich L, Forsberg M, Gogos JA, Karayiorgou M, Mannisto PT. Site specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 2007; 27: 10196-10202.
14. Kaenmaki M, Tammimaki A, Myohanen T, et al. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 2010; 114: 1745-1755.
15. Salman ED, Kadlubar SA, Falany CN. Expression and localization of cytosolic sulfotransferase (SULT) 1A1 and SULT1A3 in normal human brain. Drug Metab Dispos 2009; 37: 706-709.
16. Falany CN, Rohn-Glowacki KJ. SULT2B1: unique properties and characteristics of a hydroxysteroid sulfotransferase family. Drug Metab Rev 2013; 45: 388-400.
17. Mazei MS, Pluto CP, Kirkbride B, Pehek EA. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 2002; 936: 58-67.
18. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22: 389-395.
19. Sesack SR, Hawrylack VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998; 18: 2697-2708.
20. Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990; 55: 1067-1070.
21. Martel F, Azevedo I. An update on the extraneuronal monoamine transporter (EMT): characteristics, distribution and regulation. Curr Drug Metab 2003; 4: 313-318.
22. Vialou V, Balasse L, Dumas S, Giros B, Gautron S. Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 2007; 144: 616-622.
23. Karoum F, Chrapusta SJ, Brinjak R, Hitri A, Wyatt RJ. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br J Pharmacol 1994; 113: 1391-1399.
24. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego, Academic Press, 1997.
25. Maj J, Rogoz Z, Skuza G, Sowinska H, Superata J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 1990; 2: 101-112.
26. Mannisto PT. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors. Adv Pharmacol 1998; 42: 324-328.
27. Grahame-Smith DG, Green AR. The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol 1974; 52: 19-26.
28. Flores-Serrano AG, Vila-Luna ML, Alvarez-Cervera FJ, Heredia-Lopez FJ, Gongora-Alfaro JL, Pineda JC. Clinical doses of citalopram or reboxetine differentially modulate passive and active behaviors of female Wistar rats with high or low immobility time in the forced swimming test. Pharmacol Biochem Behav 2013; 110: 89-97.
29. Rogoz Z, Wrobel A, Krasicka-Domka M, Maj J. Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely. Pol J Pharmacol 1999; 51: 399-404.
30. Kaenmaki M, Tammimaki A, Garcia-Horsman JA, et al. Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice. Br J Pharmacol 2009; 158: 1884-1894.
31. Airavaara M, Mijatovic J, Vihavainen T, Piepponen TP, Saarma M, Ahtee L. In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 2006; 59: 321-329.
32. McClure-Begley TD, Grady SR, Marks MJ, Collins AC, Stitzel JA. Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes. Biochem Pharmacol 2014; 91: 87-96.
33. Tunbridge EM, Harrison PJ. Importance of the COMT gene for sex differences in brain function and predisposition to psychiatric disorders. Curr Top Behav Neurosci 2011; 8: 119-140.
34. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 1999; 56: 31-38.
35. Jiang H, Xie T, Ramsden D., Ho SL. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 2003; 45: 1011-1018.
36. Huotari M, Garcia-Horsman JA, Karayiorgou M, Gogos JA, Mannisto PT. D-amphetamine responses in catechol-O- methyltransferase (COMT) disrupted mice. Psychopharmacology 2004; 172: 1-10.
37. Cubeddu LX, Hoffmann IS, Talmaciu RK. Is the release of dopamine from medial prefrontal cortex modulated by presynaptic receptors? Comparison with nigrostriatal and mesolimbic terminals. Ann NY Acad Sci 1990; 604: 452-461.
38. Wolf ME, Galloway MP, Roth RH. Regulation of dopamine synthesis in the medial prefrontal cortex: studies in brain slices. J Pharmacol Exp Ther 1986; 236: 699-707.
39. Miller DK, Wong EH, Chesnut MD, Dwoskin LP. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2002; 302: 687-695.
40. Pan WH, Yang SY, Lin SK. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Synapse 2004; 53: 44-52.
41. Lei S. Cross interaction of dopaminergic and adrenergic systems in neural modulation. Int J Physiol Pathophysiol Pharmacol 2014; 6: 137-142.
42. Xing B, Li YC, Gao WJ. Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex. Brain Res 2016; Jan 11: pii: S0006-8993(16)00017-2. doi: 10.1016/j.brainres.2016.01.005
43. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998; 71: 274-280.
44. Marek GJ. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development. Int Rev Neurobiol 2007; 78: 165-192.
45. Kaariainen T. Interaction of dopaminergic and serotonergic systems in rat brain. Ph. D. Thesis, University of Kuopio, Kuopio University Publications A. Pharmaceutical Sciences 2008; 113: 1-123.
46. Raiteri L, Raiteri M. Multiple functions of neuronal plasma membrane neurotransmitter transporters. Prog Neurobiol 2015; 134: 1-16.
47. Scholze P, Norregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH. The role of zinc ions in reverse transport mediated by monoamine transporters. J Biol Chem 2002; 277: 21505-21513.
48. Muszak J, Krzymowski T, Gilun P, Stefanczyk-Krzymowska S. Countercurrent transfer of dopamine from venous blood in the cavernous sinus to the arterial blood supplying the brain -the perfused rabbit head as an experimental model. J Physiol Pharmacol 2014; 65: 641-648.
49. Krzymowski T, Stefanczyk-Krzymowska S. New facts and the concept of physiological regulation of the dopaminergic system function and its disorders. J Physiol Pharmacol 2015; 66: 331-341.